{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-115161","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2026-10-13T10:03:00+00:00","discovered_at":"2026-10-13T10:05:00.580469+00:00","generated_at":"2026-10-13T10:05:31.791729+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ArriVent BioPharma doses first patient in U.S. Phase 1 trial of ARR-002 for ovarian and endometrial cancer","bullets":["ArriVent (Nasdaq: AVBP) dosed the first patient in the U.S. Phase 1 trial (NCT07755436) of ARR-002, a MUC16/NaPi2b dual-target tetravalent ADC.","ARR-002 is a potential first-in-class MUC16/NaPi2b dual-target ADC for ovarian and endometrial cancer; both targets are highly over-expressed in these cancers.","Stuart Lutzker, President of R&D, said ARR-002 is ArriVent's second ADC to enter the clinic, broadening the pipeline beyond lung and gastrointestinal cancers.","In August 2026, ArriVent licensed ARR-002 from Shanghai Allist Pharmaceuticals for Greater China, including mainland China, Hong Kong, Macau, and Taiwan, retaining all other rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-115161","json":"https://secwatch.observer/filing/0001104659-26-115161.json","markdown":"https://secwatch.observer/filing/0001104659-26-115161.md","text":"https://secwatch.observer/filing/0001104659-26-115161.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926115161/0001104659-26-115161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926115161/tm2627450d1_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-13T10:05:31.791729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}